Clinical trial
Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer
NCT00005649 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00005649 |
|---|---|
| Title | Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer |
| Official title | An Open-Label Combination Study of Capecitabine and Standard Paclitaxel Therapy as First or Second Line Therapy in Women With Metastatic Breast Carcinoma |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, paclitaxel |
| Start date | Jul 1, 1998 |
| Primary completion | Jul 4, 2002 |
| Completion | Jul 4, 2002 |
| First posted | Apr 28, 2004 |
| Last update posted | Aug 16, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: